Traws Pharma director receives stock option grant

Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation.

Accepted by SEC EDGAR 03/10/2026 - 07:21 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation. He was awarded 31,258 options to buy common stock at an exercise price of $1.6000 per share. These options vest 100% on the first anniversary of the March 8, 2026 grant, and his reported derivative holdings after the grant are 31,258 options.

Insider Trade Summary

Grant/Award: 31,258 shares

Grant/Award 1 txn

Insider CAUTREELS WERNER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	31,258	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 31,258 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 31,258 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Traws Pharma (TRAW) report for Werner Cautreels?

Traws Pharma reported that director Werner Cautreels received a grant of 31,258 stock options. The options were awarded as compensation by the company’s independent compensation committee and give him the right to buy common shares at a fixed exercise price.

How many stock options did the Traws Pharma director receive in this Form 4?

The director received 31,258 stock options. Each option represents the right to purchase one share of Traws Pharma common stock, providing equity-based compensation that aligns the director’s potential upside with future company performance and share price appreciation.

What is the exercise price of the Traws Pharma stock options granted?

The stock options were granted with an exercise price of $1.6000 per share. This means the director can buy Traws Pharma common stock at that fixed price once the options vest, regardless of the market price at the time of exercise.

When do Werner Cautreels’ newly granted Traws Pharma options vest?

The options vest 100% on the first anniversary of the grant date. According to the disclosure, the entire 31,258-option award will become exercisable one year after the grant, rather than vesting in multiple installments over several years.

How many Traws Pharma derivative securities does the director hold after this grant?

After the grant, the director is reported to hold 31,258 derivative securities in the form of stock options. This reflects the full amount of the new award, indicating the filing shows no previously reported option position in this specific derivative table.

Is this Traws Pharma Form 4 a market purchase or sale of shares?

No, it is not a market purchase or sale. The Form 4 reports a compensation-related grant of stock options, coded as an “A” transaction, rather than an open-market buy or sell of Traws Pharma common stock on an exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAUTREELS WERNER

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		31,258		03/08/2027(1)	03/08/2036	Common Stock	31,258	$0	31,258	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Werner Cautreels	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.